PT512260E - Vectores "pur a" estaveis e suas utilizacoes - Google Patents

Vectores "pur a" estaveis e suas utilizacoes Download PDF

Info

Publication number
PT512260E
PT512260E PT92105887T PT92105887T PT512260E PT 512260 E PT512260 E PT 512260E PT 92105887 T PT92105887 T PT 92105887T PT 92105887 T PT92105887 T PT 92105887T PT 512260 E PT512260 E PT 512260E
Authority
PT
Portugal
Prior art keywords
plasmid
pura
gene
vector
virus
Prior art date
Application number
PT92105887T
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Newton Brey Iii
James Peter Fulginiti
Algis Anilionis
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of PT512260E publication Critical patent/PT512260E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
PT92105887T 1991-05-03 1992-04-06 Vectores "pur a" estaveis e suas utilizacoes PT512260E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69570691A 1991-05-03 1991-05-03

Publications (1)

Publication Number Publication Date
PT512260E true PT512260E (pt) 2001-12-28

Family

ID=24794162

Family Applications (1)

Application Number Title Priority Date Filing Date
PT92105887T PT512260E (pt) 1991-05-03 1992-04-06 Vectores "pur a" estaveis e suas utilizacoes

Country Status (16)

Country Link
US (2) US5919663A (US07311899-20071225-C00021.png)
EP (1) EP0512260B1 (US07311899-20071225-C00021.png)
JP (1) JP3320095B2 (US07311899-20071225-C00021.png)
KR (1) KR100242798B1 (US07311899-20071225-C00021.png)
AT (1) ATE202800T1 (US07311899-20071225-C00021.png)
AU (1) AU654347B2 (US07311899-20071225-C00021.png)
CA (1) CA2067862C (US07311899-20071225-C00021.png)
DE (1) DE69231907T2 (US07311899-20071225-C00021.png)
DK (1) DK0512260T3 (US07311899-20071225-C00021.png)
ES (1) ES2160573T3 (US07311899-20071225-C00021.png)
FI (1) FI111013B (US07311899-20071225-C00021.png)
GR (1) GR3036487T3 (US07311899-20071225-C00021.png)
IL (1) IL101751A0 (US07311899-20071225-C00021.png)
NO (1) NO314043B1 (US07311899-20071225-C00021.png)
PT (1) PT512260E (US07311899-20071225-C00021.png)
TW (1) TW201794B (US07311899-20071225-C00021.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
JP2001500008A (ja) * 1996-09-04 2001-01-09 ビーエーエスエフ アクチェンゲゼルシャフト アデニロスクシナート・シンセターゼ
US6010705A (en) * 1997-04-11 2000-01-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
IL132327A0 (en) * 1997-04-11 2001-03-19 Univ Louisiana State Attenuated invasive vaccines against fish pathogens
EP1169465B1 (en) * 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
KR100427587B1 (ko) * 2001-01-12 2004-04-27 주식회사 바이오리더스 신규 ｄ-글루탐산 합성효소 유전자 ｄｎａ 및 이를 이용한 항생제 비의존성 벡터
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
CN1646020A (zh) * 2002-01-31 2005-07-27 圣必健公司 将核酸和/或蛋白质导入呼吸系统的方法与制剂
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
EP2152883A4 (en) * 2007-05-10 2010-10-27 Univ Arizona RECOMBINANT BACTERIA COMPRISING VECTORS FOR THE EXPRESSION OF NUCLEIC ACID SEQUENCES ENCODING ANTIGENS
EP2150616A4 (en) 2007-05-10 2011-07-27 Univ Arizona REGULATED ANTIGEN SYNTHESIS AND / OR REGULATED ATTENUATION FOR IMPROVING VACCINATE IMMUNOGENICITY AND / OR SAFETY
WO2009046449A1 (en) 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) * 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
US8889121B2 (en) 2010-01-22 2014-11-18 The Arizona Board Of Regents For An On Behalf Of Arizona State University Bacterium comprising a regulated rfaH nucleic acid
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US20130266983A1 (en) * 2010-12-14 2013-10-10 The Regents Of The University Of California Creation of super-stable ColE1 plasmids by duplication of SL1-4 sequence and point mutations.
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
KR102006976B1 (ko) * 2019-02-26 2019-08-06 씨제이제일제당 주식회사 신규 프로모터 및 이를 이용한 퓨린 뉴클레오티드 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0025118A1 (de) * 1979-08-18 1981-03-18 Riedlinger, Rainer, Dr.-Ing. Anordnung zur akustischen Wiedergabe von Signalen, die mittels eines rechten und eines linken Stereo-Kanals darstellbar sind
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
EP0251579A3 (en) * 1986-06-24 1989-03-22 Enterovax Research Pty. Ltd. Non-antibiotic marker system
CA1340903C (fr) * 1986-08-05 2000-02-22 Transgene S.A. Procede de stabilisation d'un plasmide contenu dans une soche bacterienne et souche obtenue
JPS6427477A (en) * 1987-04-01 1989-01-30 Takeda Chemical Industries Ltd Dna and use thereof
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
EP0474646A4 (en) * 1989-03-31 1992-10-21 Washington University Bordetella vaccines
ATE190660T1 (de) * 1990-12-18 2000-04-15 Gen Hospital Corp Verbesserte impfstoffe

Also Published As

Publication number Publication date
KR100242798B1 (ko) 2000-02-01
DE69231907D1 (de) 2001-08-09
NO921729L (no) 1992-11-04
TW201794B (US07311899-20071225-C00021.png) 1993-03-11
FI921940A0 (fi) 1992-04-30
GR3036487T3 (en) 2001-11-30
FI921940A (fi) 1992-11-04
NO921729D0 (no) 1992-04-30
KR920021701A (ko) 1992-12-18
CA2067862A1 (en) 1992-11-04
AU1595992A (en) 1992-11-05
US5919663A (en) 1999-07-06
FI111013B (fi) 2003-05-15
ES2160573T3 (es) 2001-11-16
ATE202800T1 (de) 2001-07-15
DK0512260T3 (da) 2001-09-17
CA2067862C (en) 2003-12-30
JPH05192161A (ja) 1993-08-03
US5961983A (en) 1999-10-05
DE69231907T2 (de) 2001-10-18
EP0512260B1 (en) 2001-07-04
AU654347B2 (en) 1994-11-03
EP0512260A2 (en) 1992-11-11
JP3320095B2 (ja) 2002-09-03
NO314043B1 (no) 2003-01-20
IL101751A0 (en) 1992-12-30
EP0512260A3 (en) 1993-07-28

Similar Documents

Publication Publication Date Title
PT512260E (pt) Vectores "pur a" estaveis e suas utilizacoes
Cardenas et al. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens
AU623599B2 (en) Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic amp
JP3004049B2 (ja) 病原性のないｐｈｏＰ型微生物を含有するワクチン
US5851519A (en) Live vaccines
ES2268864T3 (es) Mutantes atenuados de salmonela que expresan de manera constitutiva el antigeno vi.
JP4583607B2 (ja) 感染症の治療のための弱毒化微生物
NZ237616A (en) Live vaccine, mutated environmental stress protein
SK55593A3 (en) Expresion of recombinant proteins in attenuated bacteria
JP2602970B2 (ja) ワクチン
US8137930B2 (en) Attenuated Salmonella enterica serovar paratyphi A and uses thereof
EP0465561A1 (en) Avirulent microbes and uses therefor
IL100010A (en) ALLENOMLAS non-violent strains that include a mutation in the TDC gene and immunogenic preparations that contain the above-mentioned non-violent strains of ALLENOMLAS
US5811105A (en) Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
WO1991018092A1 (en) Acid-tolerant salmonella typhi, double aro mutants thereof and use as an oral vaccine for typhoid fever
Curtiss et al. Stable recombinant avirulent Salmonella vaccine strains
PL171476B1 (en) Method of obtaining attenuated salmonella bacterium